Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Am J Med Genet C Semin Med Genet 142 C:7785
Published phase 3 trial data, including the OASIS 1 trial (Knop et al., 2023), show that high-dose oral semaglutide produced substantial body weight reduction at 68 weeks, with outcomes that approached those seen in injectable semaglutide trials, though these comparisons are not head-to-head
*Correspondence: Mateusz Maciejczyk, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Network pharmacology approaches for research of Traditional Chinese Medicines
US$ 25.77
US$ 25.44
US$ 21.97
US$ 29.44
US$ 22.43
